ReviewCurrent drug delivery2025
Latest Findings on the Effects of Gold Nanoparticles on the Storage Quality of Blood Products (2011-2022) - A Narrative Review.
Review in Current drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current Strategies in the Development of Nanoformulations to Enhance the Stability of Botox: A Systematic Review.AAPS PharmSciTech · 2025Pooled it
- Design and Application of Intelligent Local Anesthetic Nanoformulations.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A wide range of challenges are faced during the storage of blood products, including storage lesions, contamination that must be removed, and cell and protein damage due to chemicals and UV exposure. The enhancement of stability exhibited by gold nanoparticles (GNPs) is a notable advantage of these nanoparticles for the storage of blood products. The results of our review of articles from 2011 to 2022 discussing the effect of GNPs on blood products revealed that in RBCs, the dose, concentration, amount, and surface charge of GNPs significantly affect their compatibility. Purified GNPs were compatible with RBCs. Negatively charged GNPs with smaller diameters at lower concentrations were more compatible. However, in the plasma product, the nanoparticle surface modification with different agents showed greater compatibility. PEGylated nanospheres and GNPs exhibited higher albumin conformational stability than those coated with cetyltrimethylammonium bromide and rods. In the platelet product, smaller GNPs and high GNP concentrations induce platelet aggregation. PEGylation increased the platelet compatibility of GNP. The combination of GNPs with human fibrinogen and clopidogrel prevented clot formation. Finally, the findings of this investigation demonstrate that GNPs are contingent on their surface charge, dosage, and concentration.
Indexed as
Identifiers
39301911What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.